Gene · 6579
Papers2,617
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
321 to 340 of 2,617
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Molecular and Clinical Links between Drug-Induced Cholestasis and Familial Intrahepatic Cholestasis. | Int J Mol Sci | 2023 | 36982896 | PubTator, text mining | PubMed |
| MiRNAs in Hematopoiesis and Acute Lymphoblastic Leukemia. | Int J Mol Sci | 2023 | 36982511 | PubTator, text mining | PubMed |
| Laparoscopic Microwave Ablation: Which Technologies Improve the Results. | Cancers (Basel) | 2023 | 36980701 | PubTator, text mining | PubMed |
| Developmental Pharmacokinetics of Antibiotics Used in Neonatal ICU: Focus on Preterm Infants. | Biomedicines | 2023 | 36979919 | PubTator, text mining | PubMed |
| Freshwater Cyanobacterial Toxins, Cyanopeptides and Neurodegenerative Diseases. | Toxins (Basel) | 2023 | 36977124 | PubTator, text mining | PubMed |
| Preclinical assessment of drug-drug interaction of fb-PMT, a novel anti-cancer thyrointegrin αvβ3 antagonist. | Clin Transl Sci | 2023 | 36967488 | PubTator, text mining | PubMed |
| Personalized Dose of Adjuvant Imatinib in Patients with Gastrointestinal Stromal Tumors: Results from a Population Pharmacokinetic Analysis. | Drug Des Devel Ther | 2023 | 36942304 | PubTator, text mining | PubMed |
| Small molecule metabolites: discovery of biomarkers and therapeutic targets. | Signal Transduct Target Ther | 2023 | 36941259 | PubTator, text mining | PubMed |
| Mechanisms and implications in gene polymorphism mediated diverse reponses to sedatives, analgesics and muscle relaxants. | Korean J Anesthesiol | 2023 | 36935389 | PubTator, text mining | PubMed |
| Developing a Knowledge Graph for Pharmacokinetic Natural Product-Drug Interactions. | J Biomed Inform | 2023 | 36933632 | PubTator, text mining | PubMed |
| Screening and identification of key biomarkers of depression using bioinformatics. | Sci Rep | 2023 | 36914737 | PubTator, text mining | PubMed |
| Evaluation of the Potential for Cytochrome P450 and Transporter-Mediated Drug-Drug Interactions for Cilofexor, a Selective Nonsteroidal Farnesoid X Receptor (FXR) Agonist. | Clin Pharmacokinet | 2023 | 36906733 | PubTator, text mining | PubMed |
| A Brief Review on Chemoresistance; Targeting Cancer Stem Cells as an Alternative Approach. | Int J Mol Sci | 2023 | 36901917 | PubTator, text mining | PubMed |
| A Dual Coverage Monitoring of the Bile Acids Profile in the Liver-Gut Axis throughout the Whole Inflammation-Cancer Transformation Progressive: Reveal Hepatocellular Carcinoma Pathogenesis. | Int J Mol Sci | 2023 | 36901689 | PubTator, text mining | PubMed |
| Assessment of the drug-drug interaction potential for therapeutic proteins with pro-inflammatory activities. | Clin Transl Sci | 2023 | 36890677 | PubTator, text mining | PubMed |
| The pharmacogenetics of the new-generation antipsychotics - A scoping review focused on patients with severe psychiatric disorders. | Front Psychiatry | 2023 | 36873203 | PubTator, text mining | PubMed |
| Cholestasis: exploring the triangular relationship of gut microbiota-bile acid-cholestasis and the potential probiotic strategies. | Gut Microbes | 2023 | 36864554 | PubTator, text mining | PubMed |
| Phase 1 study of belinostat and adavosertib in patients with relapsed or refractory myeloid malignancies. | Cancer Chemother Pharmacol | 2023 | 36864346 | PubTator, text mining | PubMed |
| Apoptotic Mechanisms of Quercetin in Liver Cancer: Recent Trends and Advancements. | Pharmaceutics | 2023 | 36840034 | PubTator, text mining | PubMed |
| Biological Distribution after Oral Administration of Radioiodine-Labeled Acetaminophen to Estimate Gastrointestinal Absorption Function via OATPs, OATs, and/or MRPs. | Pharmaceutics | 2023 | 36839818 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/6579/papers?page=17